Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins.

• Published in: JAMA Oncology
• Main Authors: Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium for Early Detection of Lung Cancer, Guida, Florence, Sun, Nan, Bantis, Leonidas E, Muller, David C, Li, Peng, Taguchi, Ayumu, Dhillon, Dilsher, Kundnani, Deepali L, Patel, Nikul J, Yan, Qingxiang, Byrnes, Graham, Moons, Karel G M, Tjønneland, Anne, Panico, Salvatore, Agnoli, Claudia, Vineis, Paolo, Palli, Domenico, Bueno-de-Mesquita, Bas, Peeters, Petra H, Agudo, Antonio, Huerta, Jose M, Dorronsoro, Miren, Barranco, Miguel Rodriguez, Ardanaz, Eva, Travis, Ruth C, Byrne, Karl Smith, Boeing, Heiner, Steffen, Annika, Kaaks, Rudolf, Hüsing, Anika, Trichopoulou, Antonia, Lagiou, Pagona, La Vecchia, Carlo, Severi, Gianluca, Boutron-Ruault, Marie-Christine, Sandanger, Torkjel M, Weiderpass, Elisabete, Nøst, Therese H, Tsilidis, Kostas, Riboli, Elio, Grankvist, Kjell, Johansson, Mikael, Goodman, Gary E, Feng, Ziding, Brennan, Paul, Johansson, Mattias, Hanash, Samir M
• Format: Article in Journal/Newspaper
• Language: English
• Published: 2018
• Subjects: Aged; 80 and over; Biomarkers; Tumor; CA-125 Antigen; Carcinoembryonic Antigen; Female; Humans; Keratin-19; Lung Neoplasms; Male; Mass Screening; Membrane Proteins; Middle Aged; Non-Smokers; Prospective Studies; Protein Precursors; Proteolipids; ROC Curve; Risk Assessment; Risk Factors; Tomography Scanners; X-Ray Computed; Northern Sweden
• Online Access: http://hdl.handle.net/10668/12706; https://doi.org/10.1001/jamaoncol.2018.2078; https://jamanetwork.com/journals/jamaoncology/articlepdf/2687371/jamaoncology_guida_2018_br_180010.pdf; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233784/pdf

There is an urgent need to improve lung cancer risk assessment because current screening criteria miss a large proportion of cases. To investigate whether a lung cancer risk prediction model based on a panel of selected circulating protein biomarkers can outperform a traditional risk prediction model and current US screening criteria. Prediagnostic samples from 108 ever-smoking patients with lung cancer diagnosed within 1 year after blood collection and samples from 216 smoking-matched controls from the Carotene and Retinol Efficacy Trial (CARET) cohort were used to develop a biomarker risk score based on 4 proteins (cancer antigen 125 [CA125], carcinoembryonic antigen [CEA], cytokeratin-19 fragment [CYFRA 21-1], and the precursor form of surfactant protein B [Pro-SFTPB]). The biomarker score was subsequently validated blindly using absolute risk estimates among 63 ever-smoking patients with lung cancer diagnosed within 1 year after blood collection and 90 matched controls from 2 large European population-based cohorts, the European Prospective Investigation into Cancer and Nutrition (EPIC) and the Northern Sweden Health and Disease Study (NSHDS). Model validity in discriminating between future lung cancer cases and controls. Discrimination estimates were weighted to reflect the background populations of EPIC and NSHDS validation studies (area under the receiver-operating characteristics curve [AUC], sensitivity, and specificity). In the validation study of 63 ever-smoking patients with lung cancer and 90 matched controls (mean [SD] age, 57.7 [8.7] years; 68.6% men) from EPIC and NSHDS, an integrated risk prediction model that combined smoking exposure with the biomarker score yielded an AUC of 0.83 (95% CI, 0.76-0.90) compared with 0.73 (95% CI, 0.64-0.82) for a model based on smoking exposure alone (P = .003 for difference in AUC). At an overall specificity of 0.83, based on the US Preventive Services Task Force screening criteria, the sensitivity of the integrated risk prediction (biomarker) model was 0.63 ...